Breaking: Pfizer Halts Diabetes Pill Trial Due to Alarming Side Effects June 30, 2023 Unipro2013main Health, Healthcare, Healthcare Technology </p> <h2>Pfizer ended the Clinical Rrial for a Diabetes Pill</h2> <p> Pfizer ended the clinical trial for a diabetes pill called lotiglipron because they say that it was leading to elevated enzymes in the liver. Pfizer says that it will instead focus on its obesity drug called danuglipron. That’s interesting because the obesity drug market is super hot right now. On Monday, Eli Lilly presented findings claiming that their obesity treatment could help people lose a quarter of their body weight in 11 months. Drug makers are rushing to compete with the viral popularity of Ozempic and Mounjaro.<br /> <br /> Credit to : Redacted</p> <p> Please support our Sponsors here :
